Back to top
more

Mirum Pharmaceuticals (MIRM)

(Real Time Quote from BATS)

$60.10 USD

60.10
768,437

+6.71 (12.57%)

Updated Aug 7, 2025 12:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of -17.65% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

VBI Vaccines, Inc. (VBIV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?

by Zacks Equity Research

IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Celularity (CELU) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Devoid of marketed drugs, investors will focus on updates on Celularity's (CELU) pipeline candidates when it reports its fourth-quarter earnings.

Zacks Equity Research

Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings Season

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -46.15% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 2.86% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Coherus BioSciences (CHRS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of -81.13% and 20.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 20% and 11.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Is MedAvail (MDVL) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how MedAvail Holdings, Inc. (MDVL) and Mirum Pharmaceuticals, Inc. (MIRM) have performed compared to their sector so far this year.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Earnings Season Could Be Great for Mirum Pharmaceuticals (MIRM)

by Zacks Equity Research

Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 4.91% and 0.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum (MIRM)-Takeda Collaborate for Liver Disease Drug in Japan

by Zacks Equity Research

Mirum (MIRM) signs an agreement with Takeda for developing/commercializing maralixibat for Alagille syndrome, progressive familial intrahepatic cholestasis and biliary atresia, in Japan.

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -253.66% and -62.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.75% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -150.88% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?